NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 07 04:00PM ET
4.03
Dollar change
+0.23
Percentage change
6.05
%
Index- P/E- EPS (ttm)-0.57 Insider Own24.97% Shs Outstand298.36M Perf Week11.63%
Market Cap1.20B Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float223.95M Perf Month66.53%
Enterprise Value640.47M PEG- EPS next Q-0.14 Inst Own41.10% Short Float11.84% Perf Quarter92.82%
Income-167.87M P/S52.03 EPS this Y-11.29% Inst Trans13.05% Short Ratio4.88 Perf Half Y37.54%
Sales23.12M P/B1.18 EPS next Y18.84% ROA-11.96% Short Interest26.52M Perf YTD37.54%
Book/sh3.43 P/C1.91 EPS next 5Y0.83% ROE-15.59% 52W High4.09 -1.35% Perf Year45.49%
Cash/sh2.11 P/FCF- EPS past 3/5Y- -107.74% ROIC-15.45% 52W Low1.89 113.16% Perf 3Y-60.14%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-57.49% 19.95% Gross Margin-318.94% Volatility8.83% 9.14% Perf 5Y-
Dividend TTM- EV/Sales27.70 EPS Y/Y TTM-12.26% Oper. Margin-1395.34% ATR (14)0.27 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.15 Sales Y/Y TTM-35.41% Profit Margin-726.23% RSI (14)74.37 Recom1.25
Dividend Gr. 3/5Y- - Current Ratio10.15 EPS Q/Q-10.45% SMA2019.64% Beta0.60 Target Price8.33
Payout- Debt/Eq0.07 Sales Q/Q-57.45% SMA5051.38% Rel Volume1.36 Prev Close3.80
Employees596 LT Debt/Eq0.06 EarningsMay 08 AMC SMA20047.69% Avg Volume5.43M Price4.03
IPODec 11, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-10.21% -41.49% Trades Volume7,354,064 Change6.05%
Date Action Analyst Rating Change Price Target Change
Jul-07-25Resumed Leerink Partners Outperform $5
Aug-20-24Downgrade The Benchmark Company Buy → Hold
Feb-22-24Upgrade The Benchmark Company Hold → Buy $9
Dec-05-23Initiated KeyBanc Capital Markets Overweight $6
Nov-06-23Downgrade The Benchmark Company Buy → Hold
Oct-13-23Resumed Piper Sandler Overweight $20
Feb-28-23Initiated Cowen Outperform
Dec-15-22Initiated Goldman Buy $30
Nov-16-22Initiated Truist Buy $29
Dec-21-21Initiated The Benchmark Company Buy $27
Jul-07-25 04:05PM
09:11AM
Jun-25-25 04:09AM
Jun-09-25 09:13AM
Jun-03-25 12:00PM
06:45PM Loading…
Jun-02-25 06:45PM
May-30-25 01:00PM
May-21-25 11:21AM
May-14-25 05:00PM
May-12-25 03:30PM
May-09-25 07:30PM
11:22AM
03:50AM
May-08-25 06:05PM
04:05PM
12:39PM Loading…
May-07-25 12:39PM
10:45AM
Apr-29-25 03:00PM
Apr-23-25 10:14AM
Apr-16-25 11:59PM
Apr-08-25 04:05PM
Apr-03-25 04:05PM
Mar-25-25 04:30PM
Feb-28-25 02:18PM
02:43AM
Feb-27-25 10:15PM
06:15PM
04:05PM
Feb-26-25 07:55AM
Feb-11-25 04:05PM
04:05PM Loading…
Jan-21-25 04:05PM
Jan-17-25 07:53AM
Jan-15-25 10:47AM
Jan-14-25 09:25AM
Jan-13-25 09:00AM
Jan-07-25 09:11AM
Nov-21-24 04:05PM
Nov-07-24 10:05AM
Nov-05-24 11:17AM
02:11AM
Nov-04-24 11:00PM
05:55PM
04:05PM
Nov-01-24 09:06AM
Oct-22-24 04:05PM
Oct-16-24 08:58AM
Oct-04-24 09:00AM
Sep-26-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
05:13AM
Aug-07-24 12:45AM
Aug-06-24 06:15PM
04:05PM
Aug-01-24 06:32AM
Jul-31-24 09:00AM
Jul-21-24 05:37AM
Jul-09-24 12:00PM
Jun-25-24 04:05PM
Jun-13-24 05:40AM
May-28-24 04:05PM
May-13-24 06:00AM
May-08-24 11:03AM
07:01AM
04:30AM
May-07-24 08:57PM
06:05PM
06:01PM
04:05PM
May-01-24 09:00AM
Apr-30-24 10:01AM
Apr-08-24 12:05PM
Apr-03-24 04:05PM
Mar-27-24 04:30PM
Mar-26-24 05:25PM
Mar-19-24 04:05PM
Mar-11-24 09:00AM
Mar-05-24 04:30PM
Feb-26-24 06:55AM
Feb-23-24 04:30PM
Feb-22-24 08:15PM
Feb-21-24 09:22AM
07:09AM
Feb-20-24 11:00PM
07:00PM
04:57PM
04:05PM
Jan-30-24 01:02PM
Jan-23-24 04:05PM
Jan-15-24 09:30AM
Jan-03-24 09:40AM
Dec-20-23 04:05PM
Dec-16-23 01:00PM
Dec-11-23 03:30PM
Nov-16-23 04:05PM
Nov-03-23 12:05PM
10:51AM
08:42AM
05:55AM
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.